-
Apixaban (Eliquis) – Hospital Guideline
Stephan Moll, MD writes… Apixaban (Eliquis®) is FDA-approved for the prevention of stroke and systemic arterial thromboembolism in patients with atrial fibrillation (Clot Connect discussion of the approval on Dec 28th, 2012 is here). Here is the management guideline for apixaban
-
Another New Blood Thinner FDA Approved : Xarelto (Rivaroxaban)
Today the FDA approved Xarelto (Rivaroxaban) for irregular heart beat (= atrial fibrillation = a. fib). The approved dose is 20 mg once daily. The link to the FDA press release is here. The Xarelto prescribing information can be found here. Xarelto for Blood Clots in the Veins (DVT and PE)
-
Xarelto (Rivaroxaban) Approved For A. Fib
Today the FDA approved Xarelto (Rivaroxaban) for atrial fibrillation. The approved dose is 20 mg once daily. The link to the FDA press release is here. The Xarelto prescribing information can be found here. Xarelto for Venous Thromboembolism Xarelto is NOT approved at this point for treatment of DVT or PE
-
Rivaroxaban (Xarelto): Advisory Board to the FDA Recommends Approval for Atrial Fibrillation
The external advisory board to the FDA recommended today (Sept 8th, 2011) to approve Rivaroxaban (Xarelto) for the stroke prevention in atrial fibrillation. More details about the vote can be found here. Today’s recommendation is contrary to the one given by an internal FDA review committee which had recommended 2 days ago to NOT approve the…
-
Rivaroxaban (Xarelto): FDA Advisory Board Recommends Against Approval for Atrial Fibrillation
Surprise to many people today: An FDA staff report released today (Sept 6th, 2011) states that FDA reviewers recommend against the approval of rivaroxaban (Xarelto) for the atrial fibrillation indication. A detailed discussion with reasons for the recommendation can be found here. The main reason: It has not been shown that rivaroxaban is as effective as…
-
Apixaban (Eliquis) News – Plus Update On The Big Four New Oral Anticoagulants
There is a lot of appropriate interest and excitement today about one of the four new oral anticoagulants in development – Apixaban (Eliquis). Data from the large ARISTOTLE trial were published today in the NEJM, showing that in patients with atrial fibrillation Apixaban was more effective in preventing stroke and systemic thromboembolism, caused less major bleeding, and resulted…
-
Eliquis (Apixaban) News – Plus Update On The Big Four New Oral Anticoagulants
There is a lot of appropriate interest and excitement today about one of the four new blood thinners in development – Apixaban (Eliquis). Data from the large atrial fibrillation trial called ARISTOTLE were published today and show that the drug is more effective and safer than warfarin in patients with atrial fibrillation [ref 1]. This…
-
Apixaban (Eliquis): Good News
Eliquis (Apixaban) is one of the 4 promising new oral anticoagulants that (a) do not require routine monitoring of its anticoagulant effect and (b) work independently of the vitamin K pathway.
A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center
Clot Connect 